ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2026
Post-endoscopy gastric cancer in Latin America: a multicentre cohort study from Colombia.
Article in Frontiers in gastroenterology (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-endoscopy gastric cancer (PEGC), defined as gastric cancer diagnosed after a negative upper gastrointestinal endoscopy, is considered a key indicator of endoscopic quality. Although international studies estimate that PEGC accounts for 5-11% of gastric cancer cases, evidence from Latin America remains scarce. Methods: We conducted a retrospective multicentre observational study across three tertiary hospitals in Bogotá, Colombia (2024-2025). Adult patients with histologically confirmed gastric neoplasms were included. PEGC was defined as cancer diagnosed between 6 and 36 months after a negative endoscopy. Clinical characteristics, tumour location, and hospital outcomes were compared between PEGC and non-PEGC cases. Results: Amongst 599 patients, 71 met criteria for PEGC, corresponding to a frequency of 11.9% (95% CI: 9.5-14.7). Helicobacter pylori positivity was 67.1% overall and 70.4% amongst PEGC cases. PEGC was associated with higher rates of palliative management (23.9% vs 2.8%; OR 10.77; 95% CI: 5.09-22.77; p<0.001) and increased in-hospital mortality (16.9% vs 7.0%; OR 2.70; 95% CI: 1.33-5.46; p=0.004). Conclusion: PEGC was frequent in this Colombian cohort and associated with adverse hospital outcomes, highlighting missed diagnostic opportunities and the need to strengthen endoscopic quality standards in high-burden regions. These findings support the incorporation of PEGC rate as a quality indicator for upper gastrointestinal endoscopy in high-incidence regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.